Cargando…

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer

OBJECTIVE: To investigate whether BIRADS MRI characteristics before or during neoadjuvant endocrine therapy (NET) are associated with the preoperative endocrine prognostic index (PEPI) in ER+/HER2- breast cancer patients. METHODS: This retrospective observational cohort study included 35 ER+/HER2- p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ragusi, Max AA, Winter-Warnars, Gonneke AO, Wesseling, Jelle, Linn, Sabine C, Beets-Tan, Regina G, van der Velden, Bas HM, Elias, Sjoerd G, Gilhuijs, Kenneth GA, Loo, Claudette E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2021
Materias:	Full Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248214/ https://www.ncbi.nlm.nih.gov/pubmed/34142870 http://dx.doi.org/10.1259/bjr.20201125

Ejemplares similares

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
por: Ragusi, Max A.A., et al.
Publicado: (2021)

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

Harmonization of Quantitative Parenchymal Enhancement in T(1)‐Weighted Breast MRI
por: van der Velden, Bas H.M., et al.
Publicado: (2020)

Volumetric breast density estimation on MRI using explainable deep learning regression
por: van der Velden, Bas H. M., et al.
Publicado: (2020)

Synchronous Breast Cancer: Phenotypic Similarities on MRI
por: Wang, Hui, et al.
Publicado: (2019)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review
por: van der Hoogt, Kay J. J., et al.
Publicado: (2021)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

Local staging of ipsilateral breast tumor recurrence: mammography, ultrasound, or MRI?
por: Walstra, Coco J. E. F., et al.
Publicado: (2020)

Validation of Combined Deep Learning Triaging and Computer-Aided Diagnosis in 2901 Breast MRI Examinations From the Second Screening Round of the Dense Tissue and Early Breast Neoplasm Screening Trial
por: Verburg, Erik, et al.
Publicado: (2023)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Simplifying Breast Imaging Reporting and Data System classification of mammograms with pure suspicious calcifications
por: Menezes, Gisela LG, et al.
Publicado: (2017)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
por: van der Velden, Bas H. M., et al.
Publicado: (2018)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
por: Ragusi, M. A. A., et al.
Publicado: (2022)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Towards the use of diffuse reflectance spectroscopy for real-time in vivo detection of breast cancer during surgery
por: de Boer, Lisanne L., et al.
Publicado: (2018)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
por: Schrijver, Willemijne, et al.
Publicado: (2018)

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
por: Janssen, Liselore M, et al.
Publicado: (2022)

Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy
por: Hellingman, Daan, et al.
Publicado: (2019)

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
por: Janssen, L. M., et al.
Publicado: (2022)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u8l0bk3eovkftl38o7md8o1jma